Meeting Coverage:

American Academy of Ophthalmology

AAO: 2024

36 Months of GA Therapy with Pegcetacoplan

Show Description +

Dr. Dhoot highlights 3-year efficacy and safety data for pegcetacoplan (Syfovre, Apellis) for subfoveal GA; every-other-month treatment led to a 24% reduction in lesion growth at 36 months.

Posted: 10/29/2024

Up Next


Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

36 Months of GA Therapy with Pegcetacoplan

Dr. Dhoot highlights 3-year efficacy and safety data for pegcetacoplan (Syfovre, Apellis) for subfoveal GA; every-other-month treatment led to a 24% reduction in lesion growth at 36 months.

Posted: 10/29/2024


Please log in to leave a comment.

More From AAO: 2024 Coverage